Coherus BioSciences renames to Coherus Oncology, sharpens focus on cancer immunotherapy

Coherus Oncology, Inc.

Name change to Coherus Oncology, Inc. effective May 29, 2025; stock ticker CHRS unchanged.
Company now exclusively focused on proprietary immuno-oncology medicines; pipeline includes LOQTORZI, CHS-114, and casdozokitug.
LOQTORZI is a next-gen PD-1 inhibitor approved for nasopharyngeal carcinoma; CHS-114 is a CCR8 antibody in Phase 1b.
Casdozokitug, an IL-27 antagonist, is in a randomized Phase 2 study for first-line advanced metastatic HCC.
Board and scientific advisors include leaders from Cancer Research Institute, MSKCC, and HHMI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.